EML2: A Potential Drug Target and Biomarker (G24139)

Target Name: EML2

NCBI ID: G24139

EML2

EML2: A Potential Drug Target and Biomarker

EML2 (EchinodermMT-associated protein (EMAP)-like protein 70) is a protein that has been identified as a potential drug target and biomarker. It is a member of the EMAP family, which is known for their involvement in various physiological processes, including cell signaling, development, and homeostasis. EML2 has been shown to play a crucial role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-Related Characteristics

EML2 is involved in several disease-related processes that are associated with the pathogenesis of various diseases. One of the most significant functions of EML2 is its role in cancer development. EML2 has been shown to promote the growth and survival of cancer cells, and it has been identified as a potential drug target for cancer treatment.

In neurodegenerative diseases, EML2 has been implicated in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. EML2 has been shown to contribute to the pathogenesis of these diseases by promoting the production of pro-inflammatory cytokines, which can cause oxidative stress and damage to neural cells.

Autoimmune disorders, such as rheumatoid arthritis, have also been associated with EML2. EML2 has been shown to contribute to the development and maintenance of autoimmune disorders by promoting the production of immune cells that can cause inflammation and damage to tissues.

Potential Therapeutic Strategies

The potential therapeutic strategies for EML2 are vast and varied. One of the most promising strategies is the use of small molecules or antibodies to block the activity of EML2. This can be done by targeting the EML2 protein itself or by targeting the EML2-containing signaling pathways.

Another potential therapeutic strategy is the use of drugs that can inhibit the formation of EML2-containing signaling pathways. This can be done by targeting the enzymes that are involved in the formation of these pathways, such as cyclin D1, which is known to be involved in the formation of EML2.

Another approach is the use of drugs that can alter the levels of EML2 in the body. This can be done by targeting the enzymes involved in the degradation of EML2, such as ubiquitin, which is known to play a role in the degradation of EML2.

Conclusion

EML2 is a protein that has been associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases makes it a potential drug target and biomarker. The use of small molecules or antibodies to block the activity of EML2, or the use of drugs that inhibit the formation of EML2-containing signaling pathways, may be the most promising therapeutic strategies for the treatment of EML2-related diseases. Further research is needed to fully understand the role of EML2 in these diseases and to develop effective therapeutic strategies.

Protein Name: EMAP Like 2

Functions: Tubulin binding protein that inhibits microtubule nucleation and growth, resulting in shorter microtubules

The "EML2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EML2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets